- In June 2024, Mycenax partnered with Chitose Laboratory Corp. to develop a new generation of cell lines, focusing on the Supercell supercell line. This collaboration successfully transferred high-yield production clones developed by CHITOSE into the corresponding processes, utilizing its Supercell host, CHO-MK cells
- In July 2022, ProBioGen and Granite Bio announced a collaboration to provide GMP manufacturing and cell line development services. Granite Bio's lead candidate is a novel monoclonal antibody aimed at treating autoimmune and specific cancer indications. The collaboration leverages ProBioGen's DirectedLuck transposase technology, which enhances gene delivery and expression stability, ensuring high-quality and efficient cell line development
- In June 2022, FUJIFILM Corporation announced a significant investment of USD 1.6 billion to enhance and expand the cell culture manufacturing services of its subsidiary, FUJIFILM Diosynth Biotechnologies. This investment aims to bolster the capabilities of FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO), by expanding its sites in Hillerød, Denmark, and Texas, USA. The expansion includes the addition of large-scale bioreactors and downstream processing streams, making the Hillerød facility the largest end-to-end CDMO in Europe. This investment is expected to create approximately 450 jobs and support sustainable production enhancements, aligning with Fujifilm's "Green Value Climate Strategy" to achieve net zero CO2 emissions by the end of Fiscal Year 2040
Frequently Asked Questions
China is expected to witness the highest compound annual growth rate (CAGR) in the cell line development market. This growth is driven by increasing investments in biotechnology and pharmaceutical research, a growing demand for biologics and biosimilars, and the presence of a large patient population.
Demand for cell-based therapies and biologics drive growth trend driving in the global cell line development market.
